INCIDENCE OF HBV REACTIVATION IN PATIENTS WITH DIFFUSED LARGE B CELL LYMPHOMA IN ERA OF PROPHYLACTIC ANTIVIRAL THERAPY

Introduction: Patients with Diffused large B cell lymphoma (DLBCL) who are also co-infected Hepatitis virus (HBV) may experience HBV reactivation during immunochemotherapy which can delay or prematurely terminate anti-tumor treatment. It is usually considered that patients hepatitis surface antigen-positive (HBsAg+) have a higher rate of and poorer prognosis compared resolved infection (HBsAg+/anti-HBc+). However, limited data exists regarding the incidence survival outcomes in DLBCL HBsAg+ receive prophylactic antivirals HBsAg+/anti-HBc+ adopt DNA monitoring-guided antiviral strategies. Methods: newly diagnosed were received at least 4 cycles R-CHOP (rituximab, prednisone, vincristine, doxorubicin, cyclophosphamide) CHOP-like regimens between 1 January 2007 30 June 2021 Peking University Cancer Hospital reviewed retrospectively. We started on treatment from start antitumor therapy continued it for year after completion last cycle therapy. Results: A total 160 317 enrolled. Among HBsAg+, 125 (78.13%) entecavir, (18.75%) lamivudine, 5 (1.5%) adefovir telbivudine. Most adopted strategy, including 225 (71.0%) did not any therapy, while 40 (12.6%) entecavir 52 (16.40%) lamivudine. In group, 45 (28.12%) patients’ load was 10 2000 IU/mL, 55 (34.28%) had high (≥2000 IU/mL) rest negative (<10 IU/mL). While, 269 (84.86%) tested level baseline, (1.58%) (0.31%) patient After median follow-up 60.0 months, observed (6.25%) group 11(3.47%) (P = 0.139). The time beginning chemotherapy to 1.5 months (range: 1.0–4.0 months) 3.5 1.0–6.0 two groups, respectively. No experienced HBV-associated hepatitis. Conclusion: significantly lower era, even lymphoma. Keywords: Antiviral Agents; Diffuse; virus; Infections; Lymphoma, Large B-Cell, Survival research funded by: CSCO-HaoSen Oncology Research Fund 183 (Grant No. Y-HS202202-0104) Aggressive B-cell non-Hodgkin lymphoma, Immunotherapy conflicts interests pertinent abstract.